IL17A and nasopharyngitis: It is possible that nasopharyngitis and upper respiratory tract infection, albeit as two common infections in real-life settings with high incidence, are likely to have comparable incidence rates in psoriasis patients with or without using IL-17/IL-23 inhibitors.